Neurocrine Biosciences

NBIX

Market cap $15.2B

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and concludes that VMAT2 inhibitors are not clinically interchangeable Publication provides a comprehensive resource containing clinical study results, safety profiles and use considerations to support treatment decisions SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade of clinical research on two FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors – INGREZZA® (valbenazine) capsules and deutetrabenazine – for the treatment of tardive dyskinesia. Among key insights, the review highlights the distinct profiles of VMAT2 inhibitors approved for tardive dyskinesia and presents unique attributes of INGREZZA: selectivity to VMAT2, a therapeutic response at the lowest available 40 mg dose and data across a wide range of patient populations.

Nvidia earnings have cast a light on defensive areas, inducing a sector rotation that may accelerate in the short term. Looking beyond NVDA earnings, an economic environment characterized by slowing growth, persistent inflation, and tariff uncertainty is compelling investors to look beyond overbought tech. This shift favors sectors that offer resilience, stable cash flow, and intrinsic value over speculative future growth.

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with increased marketing, while Crenessity's rapid uptake suggests over $1B in peak revenue potential. The late-stage pipeline, including direclidine and osavampator, offers high-risk/high-reward opportunities that could significantly boost NBIX's value.

Neurocrine Biosciences, Inc. ( NBIX ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Kyle Gano - CEO & Director Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Phoebe Tan - Jefferies LLC, Research Division Presentation Phoebe Tan Jefferies LLC, Research Division Hi, everyone. My name is Phoebe Tan, and I am an Associate on Akash Tewari's team.

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London Piper Sandler 37th Annual Healthcare Conference.

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated.

Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.